Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP564552.RAyL_t-7h2wvxxNbjUkId1VALDSDIrW9533gmgDKZNY2Q130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP564552.RAyL_t-7h2wvxxNbjUkId1VALDSDIrW9533gmgDKZNY2Q130_assertion type Assertion NP564552.RAyL_t-7h2wvxxNbjUkId1VALDSDIrW9533gmgDKZNY2Q130_head.
- NP564552.RAyL_t-7h2wvxxNbjUkId1VALDSDIrW9533gmgDKZNY2Q130_assertion description "[Based on prior safety (MTD) data demonstrating dose-dependent, reversible, and cumulative transaminitis, and high peak plasma concentration (Cmax)-dependent changes in activated partial thromboplastin time (aPTT) with GEM 231 2-h twice-weekly infusions, an alternative schedule of GEM 231 given as a single agent was evaluated in patients with advanced solid tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP564552.RAyL_t-7h2wvxxNbjUkId1VALDSDIrW9533gmgDKZNY2Q130_provenance.
- NP564552.RAyL_t-7h2wvxxNbjUkId1VALDSDIrW9533gmgDKZNY2Q130_assertion evidence source_evidence_literature NP564552.RAyL_t-7h2wvxxNbjUkId1VALDSDIrW9533gmgDKZNY2Q130_provenance.
- NP564552.RAyL_t-7h2wvxxNbjUkId1VALDSDIrW9533gmgDKZNY2Q130_assertion SIO_000772 14751840 NP564552.RAyL_t-7h2wvxxNbjUkId1VALDSDIrW9533gmgDKZNY2Q130_provenance.
- NP564552.RAyL_t-7h2wvxxNbjUkId1VALDSDIrW9533gmgDKZNY2Q130_assertion wasDerivedFrom befree-20140225 NP564552.RAyL_t-7h2wvxxNbjUkId1VALDSDIrW9533gmgDKZNY2Q130_provenance.
- NP564552.RAyL_t-7h2wvxxNbjUkId1VALDSDIrW9533gmgDKZNY2Q130_assertion wasGeneratedBy ECO_0000203 NP564552.RAyL_t-7h2wvxxNbjUkId1VALDSDIrW9533gmgDKZNY2Q130_provenance.